Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285134811> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4285134811 endingPage "260" @default.
- W4285134811 startingPage "254" @default.
- W4285134811 abstract "Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease. Fluid-filled cysts develop and enlarge in both kidneys, eventually leading to kidney failure. Tolvaptan is a selective vasopressin V2 receptor antagonist and the first and only drug approved for treatment of ADPKD. It blocks binding of arginine vasopressin (AVP) to V2 receptors in the collecting duct of kidney, thereby inducing water diuresis (aquaresis) without losing electrolytes. Therefore, tolvaptan was originally developed and approved as the first oral aquaretic agent for treatment of hyponatremia and fluid volume overload in heart failure and cirrhosis. During the development of tolvaptan as aquaretics, efficacy of V2 antagonist in polycystic kidney animal model was reported and then the development of tolvaptan for ADPKD was also initiated. Cyclic adenosine monophosphate (cAMP) plays an important role in cyst growth by promoting cell proliferation and fluid secretion. Tolvaptan showed suppression of cyst growth through inhibiting AVP-induced cAMP production and delayed the onset of end-stage renal disease in an animal model. In the phase 3 clinical trial in ADPKD patients (TEMPO 3:4 trial), 3-year treatment with tolvaptan slowed the disease progression including increase of kidney volume and decline in renal function. Efficacy of tolvaptan in patients with late-stage ADPKD was confirmed in another 1-year phase 3 REPRISE trial. Tolvaptan is approved for treatment of ADPKD in more than 40 countries and we expect it can contribute to more ADPKD patients worldwide. We also expect that drugs with new mechanisms will be available in the near future." @default.
- W4285134811 created "2022-07-14" @default.
- W4285134811 creator A5006656973 @default.
- W4285134811 creator A5009970107 @default.
- W4285134811 creator A5022259960 @default.
- W4285134811 creator A5026616338 @default.
- W4285134811 creator A5037160906 @default.
- W4285134811 creator A5040113122 @default.
- W4285134811 creator A5040344249 @default.
- W4285134811 creator A5051554922 @default.
- W4285134811 creator A5061615524 @default.
- W4285134811 creator A5063498629 @default.
- W4285134811 creator A5073180314 @default.
- W4285134811 date "2022-01-01" @default.
- W4285134811 modified "2023-09-23" @default.
- W4285134811 title "Tolvaptan, a vasopressin V<sub>2</sub> receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)" @default.
- W4285134811 doi "https://doi.org/10.1254/fpj.22006" @default.
- W4285134811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35781456" @default.
- W4285134811 hasPublicationYear "2022" @default.
- W4285134811 type Work @default.
- W4285134811 citedByCount "0" @default.
- W4285134811 crossrefType "journal-article" @default.
- W4285134811 hasAuthorship W4285134811A5006656973 @default.
- W4285134811 hasAuthorship W4285134811A5009970107 @default.
- W4285134811 hasAuthorship W4285134811A5022259960 @default.
- W4285134811 hasAuthorship W4285134811A5026616338 @default.
- W4285134811 hasAuthorship W4285134811A5037160906 @default.
- W4285134811 hasAuthorship W4285134811A5040113122 @default.
- W4285134811 hasAuthorship W4285134811A5040344249 @default.
- W4285134811 hasAuthorship W4285134811A5051554922 @default.
- W4285134811 hasAuthorship W4285134811A5061615524 @default.
- W4285134811 hasAuthorship W4285134811A5063498629 @default.
- W4285134811 hasAuthorship W4285134811A5073180314 @default.
- W4285134811 hasConcept C126322002 @default.
- W4285134811 hasConcept C126894567 @default.
- W4285134811 hasConcept C134018914 @default.
- W4285134811 hasConcept C159641895 @default.
- W4285134811 hasConcept C170493617 @default.
- W4285134811 hasConcept C20352681 @default.
- W4285134811 hasConcept C2776266639 @default.
- W4285134811 hasConcept C2776370428 @default.
- W4285134811 hasConcept C2776703092 @default.
- W4285134811 hasConcept C2776885963 @default.
- W4285134811 hasConcept C2778653478 @default.
- W4285134811 hasConcept C2779881253 @default.
- W4285134811 hasConcept C2780091579 @default.
- W4285134811 hasConcept C2780145431 @default.
- W4285134811 hasConcept C2780615674 @default.
- W4285134811 hasConcept C71924100 @default.
- W4285134811 hasConceptScore W4285134811C126322002 @default.
- W4285134811 hasConceptScore W4285134811C126894567 @default.
- W4285134811 hasConceptScore W4285134811C134018914 @default.
- W4285134811 hasConceptScore W4285134811C159641895 @default.
- W4285134811 hasConceptScore W4285134811C170493617 @default.
- W4285134811 hasConceptScore W4285134811C20352681 @default.
- W4285134811 hasConceptScore W4285134811C2776266639 @default.
- W4285134811 hasConceptScore W4285134811C2776370428 @default.
- W4285134811 hasConceptScore W4285134811C2776703092 @default.
- W4285134811 hasConceptScore W4285134811C2776885963 @default.
- W4285134811 hasConceptScore W4285134811C2778653478 @default.
- W4285134811 hasConceptScore W4285134811C2779881253 @default.
- W4285134811 hasConceptScore W4285134811C2780091579 @default.
- W4285134811 hasConceptScore W4285134811C2780145431 @default.
- W4285134811 hasConceptScore W4285134811C2780615674 @default.
- W4285134811 hasConceptScore W4285134811C71924100 @default.
- W4285134811 hasIssue "4" @default.
- W4285134811 hasLocation W42851348111 @default.
- W4285134811 hasLocation W42851348112 @default.
- W4285134811 hasOpenAccess W4285134811 @default.
- W4285134811 hasPrimaryLocation W42851348111 @default.
- W4285134811 hasRelatedWork W10389330 @default.
- W4285134811 hasRelatedWork W12286336 @default.
- W4285134811 hasRelatedWork W14660073 @default.
- W4285134811 hasRelatedWork W14869763 @default.
- W4285134811 hasRelatedWork W15848151 @default.
- W4285134811 hasRelatedWork W17418639 @default.
- W4285134811 hasRelatedWork W3318524 @default.
- W4285134811 hasRelatedWork W8706952 @default.
- W4285134811 hasRelatedWork W9099856 @default.
- W4285134811 hasRelatedWork W9410167 @default.
- W4285134811 hasVolume "157" @default.
- W4285134811 isParatext "false" @default.
- W4285134811 isRetracted "false" @default.
- W4285134811 workType "article" @default.